Dasabuvir-sodium

Category	Hepatitis C Virus (HCV)
CAS	1132940-11-4
Description	Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b(strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively.

Quotation Now

Synonyms	Dasabuvir\|ABT-333\|exviera\|Dasabuvir sodium\|Dasabuvir sodium monohydrate
Molecular Weight	515.557
Molecular Formula	C26H26N3NaO5S
Purity	≥98% (HPLC)
Solubility	In vitro: 10 mM in DMSO
Appearance	Solid powder
Storage	Store at -20°C
In Vitro	Dasabuvir (ABT-333) sodium is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. Dasabuvir sodium inhibits the polymerase enzymatic activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC50s between 2.2 and 10.7 nM. Dasabuvir sodium inhibits replication of HCV subgenomic replicons in cell culture assays, with EC50 values of 7.7 and 1.8 nM against genotype 1a (H77) and 1b (Con1), respectively. In the presence of 40% human plasma, there is a 12- to 13-fold decrease in inhibitory potency, yielding EC50s of 99 and 21 nM for HCV genotype 1a (H77) and 1b (Con1) replicons, respectively.
PSA	106.61000
Target	IC50: 2.2 ± 0.3 nM (HCV genotype 1b N), 2.8 ± 0.2 nM (HCV genotype 1a H77), 3.1 ± 0.21 nM (HCV genotype 1b BK), 0.7 ± 1.4 nM (HCV genotype 1b Con1)